Wire · operational-macro
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 November 2026 · Fusion42 review
The FDA granted accelerated approval to neladalkib, a kinase inhibitor, for adults with previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC), based on response rates observed in a single-arm clinical trial. This provides a new oral treatment option for patients who have received prior ALK tyrosine kinase inhibitors and chemotherapy.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a new regulatory path open for oral treatments targeting ALK-positive lung cancer patients resistant to initial therapies. This approval signals increasing FDA willingness to back kinase inhibitors that address unmet needs in cancer care.
◆ Coverage
1 source · 17 Nov 2026
◆ Related on Wire
◆ Topics